More NewsRead More
SCYNEXIS to Present Data from Lead Antifungal Drug Candidate SCY-078 at 13th ASM Conference on Candida and Candidiasis
April 06, 2016
Keryx Biopharmaceuticals Announces New Appointments and Changes to its Board of Directors
April 01, 2016
SCYNEXIS, Inc. to Present at the Cowen and Company 36th Annual Health Care Conference
February 29, 2016
SCYNEXIS, Inc. to Present at Upcoming Investor Conferences
February 03, 2016
SCYNEXIS, Inc. Receives FDA Fast Track and QIDP Designations for Intravenous Formulation of SCY-078 for the Treatment of Patients with Invasive Fungal Infections
January 28, 2016
SCYNEXIS Gets SME Designation From European Medicines Agency
April 19, 2016
SCYNEXIS Offers Data Showing Support for Activity of SCY-078 Against Antifungal-Resistant Candida Strains
April 15, 2016
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here